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Abstract
Background: Interferon-γ release assay (IGRA) may improve diagnostic accuracy for latent
tuberculosis infection (LTBI). This study compared the performance of the tuberculin skin test
(TST) with that of IGRA for the diagnosis of LTBI in immunocompromised patients in an
intermediate TB burden country where BCG vaccination is mandatory.
Methods: We conducted a retrospective observational study of patients given the TST and an
IGRA, the QuantiFERON-TB Gold In-Tube (QFT-IT), at Severance Hospital, a tertiary hospital in
South Korea, from December 2006 to May 2009.
Results: Of 211 patients who underwent TST and QFT-IT testing, 117 (55%) were classified as
immunocompromised. Significantly fewer immunocompromised than immunocompetent patients
had positive TST results (10.3% vs. 27.7%, p 0.001), whereas the percentage of positive QFT-IT
results was comparable for both groups (21.4% vs. 25.5%). However, indeterminate QFT-IT results
were more frequent in immunocompromised than immunocompetent patients (21.4% vs. 9.6%, p
0.021). Agreement between the TST and QFT-IT was fair for the immunocompromised group (κ
= 0.38), but moderate agreement was observed for the immunocompetent group (κ = 0.57).
Indeterminate QFT-IT results were associated with anaemia, lymphocytopenia, hypoproteinemia,
and hypoalbuminemia.
Conclusion: In immunocompromised patients, the QFT-IT may be more sensitive than the TST
for detection of LTBI, but it resulted in a considerable proportion of indeterminate results.
Therefore, both tests may maximise the efficacy of screening for LTBI in immunocompromised
patients.
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Tuberculosis (TB) is the single most important cause of
death due to infectious disease worldwide, resulting in
~1.8 million deaths annually [1]. For effective and effi-
cient control of TB, rapid diagnosis and treatment for
active TB patients is the mainstay of national TB programs
in developing countries. However, treatment of active TB
is not sufficient to eliminate the disease, because individ-
uals with latent TB infection (LTBI) outnumber those with
active TB, and LTBI can progress to active disease at any
time [2]. For this reason, the diagnosis and treatment of
individuals with LTBI who are at higher risk of developing
active TB is an important goal of TB control programs in
developed countries [3]. However, diagnosis of LTBI is
problematic because the tuberculin skin test (TST), which
has been widely used for centuries, has several limitations.
False-positive results caused by exposure to nontuberculo-
sis mycobacteria or prior Bacille Calmette-Guerin (BCG)
vaccination, false-negative results due to cutaneous anergy
with underlying immunosuppression, interobserver vari-
ability, and the booster effect reduce the efficiency of a
strategy of targeted use of the TST and treatment of LTBI
[4-7]. To overcome the limitations of the TST, some coun-
tries have implemented interferon-γ release assays
(IGRAs) as part of their national TB programs [8-11].
IGRA tests are based on the release of interferon-γ in
blood samples after stimulation in vitro with M. tuberculo-
sis (MTB)-specific antigens [12]. IGRA tests are highly spe-
cific for diagnosing active TB and LTBI in BCG-vaccinated
individuals [13,14] and are more sensitive than the TST
for the diagnosis of active TB in immunocompromised
patients [15,16]. In addition to their improved diagnostic
accuracy, IGRA tests have operational advantages over the
TST [17]. Therefore, IGRA tests are expected to improve
the effectiveness of TB control programs in many coun-
tries with low prevalence of TB. However, the use of IGRA
tests for the diagnosis of LTBI in immunocompromised
patients is still limited, although new data are emerging
[11,18-20]. To eliminate TB, it is essential to improve the
efficiency of diagnosis and treatment of LTBI among
immunocompromised patients at high risk for develop-
ing active TB [17].
In South Korea, treatment of LTBI has been recommended
only for children aged <6 years who have been exposed to
TB, for HIV-infected individuals, for patients receiving
tumour necrosis factor-α inhibitors after diagnosis of LTBI
using the TST [21]. However, LTBI in immunocompro-
mised patients has not been adequately studied in South
Korea using the newer IGRA tests. The aim of this study
was to evaluate the performance of the TST and IGRA in
the diagnosis of LTBI infection in immunocompromised
patients compared to immunocompetent patients in
South Korea, where the incidence of active TB is interme-




Patients tested for TB infection with the TST and an IGRA,
the QuantiFERON-TB Gold In-Tube (QFT-IT), were
included in the study. Patients were tested at Severance
Hospital (Seoul, Republic of Korea), a university-affiliated
tertiary care referral hospital, between December 2006
and May 2009. We reviewed patients' medical records,
microbiologic results, other laboratory results, and radio-
graphic results. Patients who were diagnosed with active
TB during the study period or who had previously been
treated for TB were excluded to enable evaluation of LTBI.
The protocol for this study was approved by the Ethical
Review Committee of Severance Hospital. We included
211 patients who underwent both the TST and QFT-IT.
Most (197) participants were tested for suspicion of active
TB during a clinical work up by attending physicians, nine
patients underwent the tests for screening before tumour
necrosis factor-α inhibitors were administered, and five
patients before transplantation.
The definition of an immunocompromised condition
included the following: 1) diabetes mellitus 2) undergo-
ing chemotherapy for an underlying malignancy at the
time of TST and QFT-IT testing, 3) received either a solid
organ transplant or bone marrow transplant, 4) end-stage
renal disease and on renal replacement therapy, 5)
advanced liver cirrhosis with Child-Pough class C, 6) sero-
positivity for human immunodeficiency virus, 7) daily
administration of systemic corticosteroids (at least 15 mg
of prednisone per day for more than one month or com-
bination therapy with low dose corticosteroids and other
immunosuppressants including azathioprine, mycophe-
nolate, methotrexate, cyclosporine, or cyclophospha-
mide).
TST
The TST was performed by injecting a 2-TU dose of puri-
fied protein derivative RT23 (Statens Serum Institut,
Copenhagen, Denmark) intradermally into the forearm
using the Mantoux technique [22]. The criterion for a pos-
itive TST result was an induration 10 mm or greater in size
occurring 48-72 h after injection.
QFT-IT
The QFT-IT test was performed in the Immunology Labo-
ratory at Severance Hospital according to the recommen-
dations of the manufacturer (Cellestis Ltd; Carnegie,
Australia) Briefly, 1 ml blood was drawn directly into each
of three evacuated blood collection tubes: one containing
heparin alone (the nil tube, or the negative control); one
containing the T cell mitogen phytohemagglutinin (the
mitogen tube, or the positive control); and one contain-
ing the MTB-specific antigens ESAT-6, CFP-10, and TB7.7
(the TB antigen tube). After mixing, the tubes were incu-
bated upright for 20 h at 37°C before plasma was har-Page 2 of 8
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analysis within 5 days. The concentration of interferon-γ
in each plasma sample was determined using QFT ELISA.
Results were calculated using the QFT-IT software pro-
vided by the manufacturer.
Statistical analysis
Data are expressed as number (percentage) or median and
interquartile range (because the majority of data did not
follow a normal distribution). Categorical variables were
analysed using Pearson's χ2 test or Fisher's exact test; con-
tinuous variables were analysed using Mann-Whitney U
tests. The concordance between the TST and QFT-IT test
results was assessed using κ coefficients and was inter-
preted according to the Landis and Koch's classification
[23].
All tests of significance were two-tailed; P < 0.05 was con-
sidered significant. SPSS v. 11.5 (SPSS Inc., Chicago, IL,
USA) was used for statistical analyses.
Results
Baseline clinical characteristics of participants
A total of 211 participants underwent both TST and QFT-
IT testing for TB infection. Baseline characteristics of par-
ticipants are shown in Table 1. Of the 211 participants,
117 (55%) were defined as immunocompromised
because of underlying disease: 40 patients undergoing
treatment with immunosuppressive drugs, 23 with diabe-
tes, 28 with solid cancer undergoing anti-cancer chemo-
therapy, 7 with haematologic malignancies and
chemotherapy, 11 with organ transplantation, 6 with end-
stage renal disease, 1 with advanced liver cirrhosis, and 1
with HIV infection. No significant differences were
observed between the immunocompromised and immu-
nocompetent groups in terms of the distribution of age,
sex, body mass index, history of smoking, positive history
of recent TB contact, presence of a TB scar on simple chest
radiographs, white blood cell count, number of platelets,
or serum level of cholesterol. However, in laboratory find-
ings, the concentration of haemoglobin, number of lym-
phocytes, and serum levels of protein and albumin were








Age, median (range) 55 (19-98) 53 (19-98) 55 (19-93) 0.13
Male/female 97/114 45/49 52/65 0.62
BMI (median, IQR) 21.6 (19.5-24.5) 21.2 (18.8-23.9) 22.2 (19.9-25.0) 0.09
History of smoking 34 (16) 14 (15) 20 (17) 0.19
History of recent TB contact
Negative 181 (85.8) 85 (90.4) 96 (82.1)
Positive 2 (0.9) 2 (2.1) 0 (0) 0.22*
Unknown 28 (13.3) 7 (7.4) 21 (17.9)
Presence of TB scar on chest X-ray 7 (3.3) 5 (5.3) 2 (1.7) 0.25
Laboratory findings (median, IQR)
WBC (103/uL) 7350 (5480-10570) 7260 (5900-9380) 7430 (5030-11280) 0.89
Haemoglobin (g/dL) 11.1 (9.5-12.7) 11.9 (10.75-13.4) 10.6 (9.2-12.0) < 0.001
Platelets (103/uL) 272 (196-380) 277 (210-394) 266 (170-379) 0.16
Lymphocytes (103/uL) 1410 (860-1890) 1670 (1155-2085) 1230 (755-1700) < 0.001
Total protein (g/dL) 6.8 (6.1-7.38) 7.2 (6.7-7.6) 6.5 (5.7-7.0) < 0.001
Albumin (g/dL) 3.6 (2.9-4.2) 4.0 (3.2-4.4) 3.2 (2.8-3.9) < 0.001
Cholesterol (mg/dL) 152 (122-184) 160 (128-184) 149 (117-182) 0.14
Disease associated with immunosuppression 117 (55)
Diabetes 23 (11)
Solid cancer treated with anticancer chemotherapy 28 (13)
Haematologic malignant disease 7 (3)
Transplantation 11(5)
ESRD on renal replacement therapy 6 (3)
Liver cirrhosis, Child-Pough class C 1 (0.5)
HIV infection 1 (0.5)
Treated with immunosuppressive drugs† 40 (19)
Data are presented as numbers (percentages) unless otherwise indicated.
BMI, body mass index; ESRD, end-stage renal disease; IQR, interquartile range; TB, tuberculosis; WBC, white blood cells.
*p 0.22 for the difference in the history of recent TB contact, excluding participants whose history of recent TB contact was unknown.
†Patients receiving systemic corticosteroids (at least 15 mg of prednisone per day for more than one month) or combination therapy with low dose 
corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide.Page 3 of 8
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than in the immunocompetent group (Table 1).
Performance of the TST and QFT-IT in immunocompetent 
and immunocompromised patients
Overall, the TST showed positive results in 38 patients
(18%) and negative results in 173 patients (82%),
whereas the QFT-IT showed positive results in 49 patients
(23.2%) and negative results in 128 patients (60.7%).
Thirty-four patients (16.1%) had indeterminate QFT-IT
assay results. The proportion of positive TST results was
higher in the immunocompetent group (27.7%) than in
the immunocompromised group (10.3%, p 0.001). For
the QFT-IT, the proportion of positive results was compa-
rable for both groups (25.5% vs 21.4%, p 0.068); how-
ever, the proportion of indeterminate results was higher
in the immunocompromised group than in the immuno-
competent group (21.4% vs 9.6%, p 0.021; Table 2).
Concordance between the TST and QFT-IT in 
immunocompetent and immunocompromised patients
Table 3 shows the concordance between the TST and QFT-
IT. The TST and QFT-IT assays showed moderate agree-
ment in the immunocompetent group (κ = 0.57, p 0.001).
However, agreement was fair in the immunocompro-
mised group (κ = 0.38, p 0.001). Agreement between the
TST and QFT-IT did not show a remarkable change (κ =
0.40, p 0.001) when we used a 5-mm induration cut off
for the TST in the immunocompromised group.
Clinical characteristics of patients with indeterminate 
results for the QFT-IT
Table 4 shows the characteristics of 34 patients with inde-
terminate QFT-IT results and the remaining 117 patients
with determinate results. Immunosuppressive conditions,
low levels of haemoglobin, leukocytosis, lymphocytope-
nia, hypoproteinemia, and hypoalbuminemia were more
frequently observed in patients with indeterminate than
determinate results. Only one patient (3%) with indeter-
minate QFT-IT results showed a positive TST result. In the
multivariate analysis, lymphocytopenia (odds ratio [OR]
0.998, 95% confidence interval [CI] 0.997-0.998) and
cholesterol level (OR 1.01, 95% CI 1.002-1.024) were
independently associated with the indeterminate QFT-IT
results. Hypoalbuminemia showed marginal significance
(OR 0.288, 95% CI 0.080-1.040, p 0.057).
Discussion
Among our 211 participants, including 117 (55%) immu-
nocompromised patients, the number of patients with
positive QFT-IT results was comparable between the
immunocompetent and immunocompromised groups
(25.5% vs 21.4%, respectively), whereas the TST detected
significantly less LTBI among the immunocompromised
group than the immunocompetent group (27.7% vs
10.3%). In addition, for the 177 patients with determi-
nate QFT-IT and TST results, the proportions of positive
results for the TST and QFT-IT were significantly different
among the immunocompromised group (27.2% vs
13.0%, respectively) but were comparable among the
immunocompetent group (29.4% vs 28.2%, respec-
tively). These findings suggest that the sensitivity of the
QFT-IT for the diagnosis of LTBI infection might be higher
than that of the TST in immunocompromised patients.
The results of our study are consistent with those of previ-
ous studies reporting the higher sensitivity of the IGRA
test compared to the TST [18,20,24] for the diagnosis of
TB infection. The false-negative results of the TST may
result from poor cell-mediated immunity [22]; concerns
have frequently been raised regarding the effects of cuta-
neous anergy in immunosuppressive conditions on the
results of the TST, and this issue has been considered a
weak point of the TB elimination strategy [6,17]. There-
fore, the higher sensitivity of in vitro IGRA tests for the
diagnosis of LTBI in immunocompromised patients could
strengthen the targeted testing strategy and treatment of
LTBI.
Table 2: Results of the TST and QFT-IT in 211 participants who underwent evaluation for tuberculosis infection







Positive* 38 (18) 26 (27.7) 12 (10.3)
Negative 173 (82) 68 (72.3) 105 (89.7)
QFT-IT
Positive† 49 (23.2) 24 (25.5) 25 (21.4)
Negative 128 (60.7) 61 (64.9) 67 (57.3)
Indeterminate‡ 34 (16.1) 9 (9.6) 25 (21.4)
Data are presented as numbers (percentages) unless otherwise indicated.
QFT-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
*p 0.001 for the difference in the number of positive TST results between the groups.
†p 0.068 for the difference of QFT-IT results between the groups.
‡p 0.021 for the difference in the proportion of indeterminate QFT-IT results between the groups.Page 4 of 8
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:207 http://www.biomedcentral.com/1471-2334/9/207The moderate concordance between the TST and QFT-IT
(κ = 0.57, p < 0.001) in the immunocompetent group in
contrast with the fair concordance of the TST and QFT-IT
(κ = 0.38, p 0.001) in the immunocompromised group
revealed that more patients had TST negative/QFT-IT pos-
itive results in the immunocompromised group. Consid-
ering the high specificity of the QFT-IT for MTB infection
[12], these results suggest that a substantial proportion of
immunocompromised patients with LTBI may be missed
by the TST. However, half of the discordant results of the
immunocompetent group resulted from a TST positive/
QFT-IT negative, raising concern for the low sensitivity of
the QFT-IT. Considering that the TB infection rate in 20-
to 29-year-old Koreans was 59% in 1995 [25] and more
than half of the participants in our study were > 50 years,
there was a possibility for false negative QFT-IT results
estimating latent TB infection. Furthermore, a large con-
tact investigation of a South Korean high-school outbreak
showed that more than 20% of the contacts with a posi-
tive on the TST with more than 20 mm induration, but
with a negative QuantiFERON-TB Gold assay, were diag-
nosed with active TB in BCG vaccination circum-
stances[26]. Therefore, it is difficult to disregard the
possibility of a true M. TB infection among the three
immunocompromised patients with a TST positive/QFT-
IT negative in our study.
Although our results suggest that the QFT-IT improves the
accuracy of the diagnosis of LTBI in immunocompro-
mised groups, the QFT-IT had a considerable proportion
of indeterminate results in the immunocompromised
group (21.4%). In this study, indeterminate results for the
QFT-IT occurred at a relatively high rate compared to in
previous studies, which ranged from 1-21% [27-29]. The
relatively high proportion of indeterminate results could
be explained by either local or systemic inflammatory
conditions affecting the participants in our study when
the QFT-IT tests were performed in routine clinical prac-
tice. Laboratory findings of lymphocytopenia but relative
leukocytosis associated with indeterminate QFT-IT results
suggest that the immunocompromised patients had a
combination of inflammatory and immunosuppressive
conditions, along with hypoalbuminemia, which indi-
cates poor nutritional status. These results are consistent
with previously reported risk factors for indeterminate
QFT-IT results [29]. It is interesting that only one patient
with indeterminate QFT-IT results had a positive TST
result, with a 12-mm induration; the other 33 patients
showed negative TST results without any induration.
These results suggest that most of these patients showed
an anergic response to the stimulus; however, not all
patients with indeterminate QFT-IT results had negative
TST results in previous studies [20], which implies that
individuals with an indeterminate QFT-IT result may in
fact have LTBI.
In South Korea, the TB infection rate in 20- to 29-year-olds
was 59% in 1995, and the expected prevalence of LTBI in
all Koreans is ~30% [14,25]. Treatment of LTBI is recom-
mended only for exposed children aged <6 years, HIV-
infected individuals, and patients receiving tumour necro-
sis factor-α inhibitors only after diagnosis of LTBI infec-
tion by TST [21]. Although the treatment of LTBI has not
been recommended for other immunocompromised
Table 3: Diagnostic agreement of TST and QFT-IT (κ) *
QFT-IT + QFT-IT - Total κ
All participants 0.48
TST + 26 (14.7) 11 (6.2) 37
TST - 23 (13.0) 117 (66.1) 140
Total 49 128 177
Immunocompetent group 0.57
TST + 17 (20.0) 8 (9.4) 25
TST - 7 (8.2) 53 (62.4) 60
Total 24 61 85
Immunocompromised group 0.38
TST+ 9 (9.8) 3 (3.3) 12
TST - 16 (17.4) 64 (69.6) 80
Total 25 67 92
Immunocompromised group* 0.40
TST+* 14 (15.2) 11 (12.0) 25
TST -* 11 (12.0) 56 (60.9) 67
Total 25 67 92
Data are presented as numbers (percentages) unless otherwise indicated.
QFT-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
*Agreement between the two tests with a 5-mm induration cut off for the TST in the immunocompromised group.Page 5 of 8
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transplantation or immunosuppressive treatments such as
steroids, or those who have end-stage renal disease or
malignancy treated with anti-cancer chemotherapy, physi-
cians have become increasingly interested in the treat-
ment of LTBI. Although the prevalence of active TB is
decreasing, the number of immunocompromised hosts is
increasing, and these patients are vulnerable to progres-
sion from LTBI to active TB. Therefore, given the possibil-
ity of false-negative TST results in the
immunocompromised group in our study, the diagnosis
of LTBI using TST only could miss a substantial number of
candidates for treatment of LTBI infection in South Korea.
Some more recent guidelines for the diagnosis of LTBI
include a two-step process using the TST followed by
IGRA in cases in which the TST result is positive [30].
However, considering the poor compliance with the
repeated visit required for two-step TST and IGRA testing,
and the considerable number of individuals with TST neg-
ative/QFT-IT positive results in the immunocompromised
group in our study, the use of both the TST and QFT-IT
tests could maximise the efficacy of screening for LTBI in
immunocompromised patients.
To fully understand our results, it is necessary to consider
the limitations of this study. First, the accuracy of the TST
and QFT-IT for the diagnosis of LTBI infection could not
be directly estimated in our study because there were no
methods to confirm the diagnosis. Second, the study did
not include long-term follow-up data for progression to
active TB in conjunction with the results of the TST and
QFT-IT. Therefore, we could not conclusively demonstrate
the superiority of the QFT-IT for the diagnosis of LTBI
among immunocompromised patients. Third, no data
were included regarding the BCG vaccination status of
participants, and therefore the effect of BCG vaccination
on the TST and QFT-IT results of immunocompetent and
immunocompromised patients could not be analysed.
However, because BCG vaccination is mandatory in South
Korea, and the age distribution of the two groups was sim-
ilar, we do not expect BCG vaccination to have greatly
affected our results. Fourth, the heterogeneous nature and






Age, median (range) 61 (20-98) 54 (19-85) 0.52
Male/female 13/21 84/93 0.32
BMI, (median, IQR) 21.6 (20.8-25.4) 21.5 (19.2-24.4) 0.28
Recent TB contact 1.0*
Negative 25 (73.5) 156 (88.1)
Positive 0 (0) 2 (1.1)
Unknown 9 (26.5) 19 (10.7)
Presence of TB scar on chest X-ray 0 (0) 7 (4.0) 0.24
History of smoking 4 (12) 30 (17) 0.44
Hypertension 12 (35) 37 (21) 0.07
Positive results of TST 1 (3) 49 (28) 0.002
Immunosuppressive condition 25 (74) 92 (52) 0.02
Diabetes 3 20
Solid cancer treated with anticancer chemotherapy 2 26
Haematologic malignant disease 2 5
Transplantation 4 7
ESRD on renal replacement therapy 1 5
Liver cirrhosis, Child-Pough class C 0 1
HIV infection 0 1
Treated with immunosuppressive drugs 13 27
Laboratory findings, (median, IQR)
WBC (103/uL) 10 695 (4840-16275) 7160 (5510-9660) 0.04
Haemoglobin (g/dL) 9.9 (8.9-10.9) 11.5 (9.8-13.1) < 0.001
Platelets (103/uL) 317 (214-399) 267 (196-376) 0.43
Lymphocytes (103/uL) 780 (435-1582) 1500 (1005-1925) < 0.001
Total protein (g/dL) 6.45 (5.3-6.8) 6.9 (6.2-7.4) < 0.001
Albumin (g/dL) 3.0 (2.7-3.2) 3.8 (3.1-4.2) < 0.001
Cholesterol (mg/dL) 138 (109-182) 156 (125-184) 0.12
Data are presented as numbers (percentages) unless otherwise indicated.
MI, body mass index; ESRD, end-stage renal disease; IQR, interquartile range; QFT-IT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis; TST, 
tuberculin skin test; WBC, white blood cells.
*p 1.00 for the difference in history of recent TB contact, except where unknown.Page 6 of 8
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made it difficult to generalize among the various immu-
nocompromised conditions.
Conclusions
In conclusion, compared with the TST, the QFT-IT assay
seems to be more sensitive for detecting LTBI in immuno-
compromised patients; however, the QFT-IT gave a con-
siderable proportion of indeterminate results among
immunocompromised patients. Therefore, the use of
both the TST and QFT-IT could maximize the efficacy of
screening for LTBI in immunocompromised patients.
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